Molina Healthcare 2026Q3 调整后EPS $0.89同比降53%、MCR升至92.9%，重申全年调整后EPS≥$5.25指引并称Medicaid利润率或现拐点，盘后跌约4.8%

----- moh-20261021.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM
8-K
______________
Current Report
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 21, 2026
______________
MOLINA HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)
Delaware
1-31719
13-4204626
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
______________
200 Oceangate, Suite 100,
Long Beach,
California
90802
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (
562
)
435-3666
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 Par Value
MOH
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.
☐
Item 2.02.    Results of Operations and Financial Condition.
On October 21, 2026, Molina Healthcare, Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2026 and reaffirming the Company’s full-year 2026 earnings guidance. The full text of the press release is included as Exhibit 99.1 to this report. The information contained in the Company’s website cited in the press release is not part of this report.
Note: The information in this Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.    Financial Statements and Exhibits.
(d)     Exhibits:
Exhibit No.
Description
99.1
Press release of Molina Healthcare, Inc., issued October 21, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLINA HEALTHCARE, INC.
Date:
October 21, 2026
By:
/s/ Jeff D. Barlow
Jeff D. Barlow
Chief Legal Officer and Secretary

----- moh3q26_er.htm -----
EX-99.1
2
moh3q26_er.htm
EX-99.1
Document
News Release
Investor Contact:
Jeffrey Geyer,
Jeffrey.Geyer@molinahealthcare.com
, 305-317-3012
Media Contact:
Caroline Zubieta,
Caroline.Zubieta@molinahealthcare.com
, 562-542-1845
Molina Healthcare Reports Third Quarter 2026 Financial Results
Reaffirms Full Year 2026 Earnings Guidance
Long Beach, Calif., October 21, 2026
– Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported third quarter 2026 GAAP income per diluted share of $0.73 and adjusted income per diluted share of $0.89. Financial results are summarized below:
Three months ended
Nine months ended
September 30,
September 30,
2026
2025
2026
2025
(In millions, except per-share results)
Premium Revenue
$10,457
$10,841
$30,873
$32,337
Total Revenue
$11,082
$11,477
$32,752
$34,051
GAAP:
Net Income
$38
$79
$112
$632
EPS – Diluted
$0.73
$1.51
$2.19
$11.79
Medical Care Ratio (MCR)
92.9
%
92.6
%
92.1
%
90.8
%
G&A Ratio
6.4
%
6.4
%
6.8
%
6.5
%
Pre-tax Margin
0.5
%
0.8
%
0.5
%
2.4
%
Adjusted:
Net Income
$46
$97
$243
$724
EPS – Diluted
$0.89
$1.84
$4.74
$13.49
G&A Ratio
6.3
%
6.3
%
6.6
%
6.4
%
Pre-tax Margin
0.6
%
1.0
%
1.1
%
2.7
%
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.
Quarter Highlights
•
As of September 30, 2026, the Company served approximately 4.9 million members.
•
Premium revenue was approximately $10.5 billion for the third quarter of 2026.
•
Third quarter 2026 GAAP income per diluted share was $0.73 and adjusted income per diluted share was $0.89.
•
The Company reaffirmed its full year 2026 guidance of expected premium revenue of approximately $42 billion and adjusted earnings of at least $5.25 per diluted share.
“We are pleased with our third quarter results in this challenging environment and reaffirm our full year guidance,” said Joseph Zubretsky, President and Chief Executive Officer. “With the apparent plateauing of medical cost trend, which remains at elevated levels, and the strength of recent rate updates for 2027, we believe we are likely observing the beginning of the turn in Medicaid margins.”
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 2
October 21, 2026
Premium Revenue
Premium revenue was approximately $10.5 billion for the third quarter of 2026, a decrease of 4% year over year. The lower premium revenue reflects the impact of lower membership in Medicaid and Marketplace, partially offset by rate updates.
Net Income
GAAP net income for the third quarter of 2026 was $38 million, or $0.73 per diluted share, a decrease of 52% year over year. Adjusted net income for the third quarter of 2026 was $46 million, or $0.89 per diluted share, a decrease of 53% year over year. The decrease is attributed mainly to a higher consolidated MCR.
Medical Care Ratio (MCR)
•
The consolidated MCR for the third quarter of 2026 was 92.9%.
•
The Medicaid MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting rate updates and stable medical cost trend.
•
The Medicare MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting stable medical cost trend.
•
The Marketplace MCR for the third quarter of 2026 was 92.5% and in line with normal seasonality and the Company’s expectations.
General and Administrative Expense Ratio
The G&A ratio and the adjusted G&A ratio for the third quarter of 2026 were 6.4% and 6.3%, respectively, reflecting continued operating discipline.
Balance Sheet
Cash and investments at the parent company were approximately $608 million as of September 30, 2026, compared to $223 million as of December 31, 2025.
Days in claims payable at September 30, 2026, was 44, consistent with June 30, 2026.
Cash Flow
Operating cash flow for the nine months ended September 30, 2026, was $629 million, compared to an outflow of $237 million for the nine months ended September 30, 2025. The increase compared to the prior year was driven mainly by lower government receivable and payable settlements in 2026.
2026 Guidance
Premium revenue guidance for the full year is unchanged at approximately $42 billion.
The Company expects its full year 2026 GAAP earnings to be at least $2.38 per diluted share and reaffirmed its full year 2026 adjusted earnings of at least $5.25 per diluted share. Guidance metrics across all segments are also reaffirmed. Full year earnings guidance includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027.
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 3
October 21, 2026
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s third quarter ended September 30, 2026 results, at 8:00 a.m. Eastern Time on Thursday, October 22, 2026. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 6534841. A telephonic replay of the conference call will be available through Thursday, October 29, 2026, by dialing (855) 669-9658 and entering confirmation number 4361465
.
A live audio broadcast of this conference call will be available on Molina Healthcare’s investor relations website,
investors.molinahealthcare.com
. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit
molinahealthcare.com
.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements. The Company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this earnings release and the Company’s accompanying oral remarks may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as “guidance,” “future,” “anticipates,” “assumes,” “believes,” “embedded,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding the Company’s 2026 guidance and long-term performance outlook, trends with respect to rates, pretax margins, utilization, and medical costs, including the timing thereof and the anticipated impact on the Company’s business, and our management’s plans and objectives for future operations and business strategy.
Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025, which is on file with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Reports on Form 10-Q for the period ended March 31, 2026 and June 30, 2026 filed with the SEC and Quarterly Report on Form 10-Q for the period ended September 30, 2026, to be filed with the SEC.
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at
sec.gov
. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of October 21, 2026, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 4
October 21, 2026
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended
Nine Months Ended
September 30,
September 30,
2026
2025
2026
2025
(In millions, except per-share amounts)
Revenue:
Premium revenue
$
10,457
$
10,841
$
30,873
$
32,337
Premium tax revenue
500
506
1,509
1,325
Investment income
102
108
301
322
Other revenue
23
22
69
67
Total revenue
11,082
11,477
32,752
34,051
Operating expenses:
Medical care costs
9,719
10,044
28,429
29,352
General and administrative expenses
710
729
2,213
2,214
Premium tax expenses
500
506
1,509
1,325
Depreciation and amortization
38
45
117
151
Impairment
—
—
93
—
Other
9
16
57
66
Total operating expenses
10,976
11,340
32,418
33,108
Operating income
106
137
334
943
Interest expense
53
49
161
140
Income before income tax expense
53
88
173
803
Income tax expense
15
9
61
171
Net income
$
38
$
79
$
112
$
632
Net income per share – Diluted
$
0.73
$
1.51
$
2.19
$
11.79
Diluted weighted average shares outstanding
51.5
52.5
51.3
53.6
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 5
October 21, 2026
MOLINA HEALTHCARE, INC.
CONSOLIDATED BALANCE SHEETS
September 30,
December 31,
2026
2025
Unaudited
(Dollars in millions,
except per-share amounts)
ASSETS
Current assets:
Cash and cash equivalents
$
4,479
$
4,248
Investments
4,100
4,008
Receivables
3,359
3,533
Prepaid expenses and other current assets
576
655
Total current assets
12,514
12,444
Property, equipment, and capitalized software, net
324
301
Goodwill and intangible assets, net
2,073
2,195
Restricted investments
345
299
Deferred income taxes, net
267
178
Other assets
129
147
Total assets
$
15,652
$
15,564
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable
$
4,988
$
4,887
Amounts due government agencies
1,141
1,326
Accounts payable, accrued liabilities and other
1,183
1,093
Deferred revenue
82
66
Total current liabilities
7,394
7,372
Long-term debt
3,771
3,766
Finance lease liabilities
179
184
Other long-term liabilities
153
173
Total liabilities
11,497
11,495
Stockholders’ equity:
Common stock, $0.001 par value, 150 million shares authorized; outstanding: 52 million shares at September 30, 2026, and 51 million at December 31, 2025
—
—
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding
—
—
Additional paid-in capital
536
452
Accumulated other comprehensive (loss) income
(95)
15
Retained earnings
3,714
3,602
Total stockholders’ equity
4,155
4,069
Total liabilities and stockholders’ equity
$
15,652
$
15,564
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 6
October 21, 2026
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended
September 30,
2026
2025
(In millions)
Operating activities:
Net income
$
112
$
632
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization
117
151
Deferred income taxes
(54)
37
Share-based compensation
85
27
Impairment
93
—
Other, net
(21)
(2)
Changes in operating assets and liabilities:
Receivables
174
(118)
Prepaid expenses and other current assets
11
(25)
Medical claims and benefits payable
101
(157)
Amounts due government agencies
(185)
(467)
Accounts payable, accrued liabilities and other
88
(195)
Deferred revenue
16
(44)
Income taxes
92
(76)
Net cash provided by (used in) operating activities
629
(237)
Investing activities:
Purchases of investments
(1,245)
(607)
Proceeds from sales and maturities of investments
1,020
1,017
Purchases of property, equipment, and capitalized software
(94)
(102)
Net cash paid in business combinations
—
(245)
Other, net
(9)
19
Net cash (used in) provided by investing activities
(328)
82
Financing activities:
Proceeds from borrowings under credit facility and term loans
—
1,100
Common stock purchases
—
(1,000)
Repayment of credit facility and term loans
—
(360)
Common stock withheld to settle employee tax obligations
(15)
(37)
Other, net
(16)
35
Net cash used in financing activities
(31)
(262)
Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents
270
(417)
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period
4,348
4,741
Cash, cash equivalents, and restricted cash and cash equivalents at end of period
$
4,618
$
4,324
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 7
October 21, 2026
MOLINA HEALTHCARE, INC.
UNAUDITED SEGMENT DATA
(Dollars in millions)
September 30,
December 31,
September 30,
2026
2025
2025
Ending Membership by Segment:
Medicaid
4,372,000
4,568,000
4,639,000
Medicare
222,000
262,000
266,000
Marketplace
267,000
655,000
713,000
Other
1,000
6,000
10,000
Total
4,862,000
5,491,000
5,628,000
Three Months Ended September 30,
2026
2025
Premium Revenue
Medical
Margin
MCR
(1)
Premium Revenue
Medical
Margin
MCR
(1)
Medicaid
$
8,199
$
577
93.0
%
$
8,015
$
639
92.0
%
Medicare
1,616
113
93.0
1,610
103
93.6
Marketplace
642
48
92.5
1,197
53
95.6
Other
(2)
—
—
NM
19
2
NM
Consolidated
$
10,457
$
738
92.9
%
$
10,841
$
797
92.6
%
Nine Months Ended September 30,
2026
2025
Premium Revenue
Medical
Margin
MCR
(1)
Premium Revenue
Medical
Margin
MCR
(1)
Medicaid
$
24,175
$
1,793
92.6
%
$
24,174
$
2,127
91.2
%
Medicare
4,698
413
91.2
4,686
436
90.7
Marketplace
1,994
233
88.3
3,401
411
87.9
Other
(2)
6
5
NM
76
11
NM
Consolidated
$
30,873
$
2,444
92.1
%
$
32,337
$
2,985
90.8
%
(1)
The MCR represents medical costs as a percentage of premium revenue.
(2) The Other MCRs are not meaningful.
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 8
October 21, 2026
MOLINA HEALTHCARE, INC.
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
Nine Months Ended
September 30,
2026
2025
Unaudited
Medical claims and benefits payable, beginning balance
$
4,887
$
4,640
Components of medical care costs related to:
Current year
28,781
29,476
Prior year
(352)
(124)
Total medical care costs
28,429
29,352
Payments for medical care costs related to:
Current year
24,692
25,425
Prior year
3,963
4,059
Total paid
28,655
29,484
Acquired balances, net of post-acquisition adjustments
—
361
Change in non-risk and other payables
327
(25)
Medical claims and benefits payable, ending balance
$
4,988
$
4,844
Days in Claims Payable
(1)
44
46
__________________
(1)
The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company’s consolidated financial statements.
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 9
October 21, 2026
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)
The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Adjustments
represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, impairments, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted G&A Ratio
represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income
represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income per diluted share
represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
Adjusted pre-tax margin
represents adjusted income before income tax expense, divided by total revenue.
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Amount
Per Diluted Share
Amount
Per Diluted Share
Amount
Per Diluted Share
Amount
Per Diluted Share
GAAP Net income
$
38
$
0.73
$
79
$
1.51
$
112
$
2.19
$
632
$
11.79
Adjustments:
Amortization of intangible assets
$
10
$
0.19
$
20
$
0.37
$
29
$
0.56
$
73
$
1.35
Acquisition-related expenses
(1)
—
—
4
0.07
33
0.61
46
0.86
Impairment
(2)
—
—
—
—
93
1.82
—
—
Other
(3)
—
—
(1)
(0.01)
21
0.44
1
0.02
Subtotal, adjustments
10
0.19
23
0.43
176
3.43
120
2.23
Income tax effect
(2)
(0.03)
(5)
(0.10)
(45)
(0.88)
(28)
(0.53)
Adjustments, net of tax
8
0.16
18
0.33
131
2.55
92
1.70
Adjusted net income
$
46
$
0.89
$
97
$
1.84
$
243
$
4.74
$
724
$
13.49
__________________
(1)
Reflects non-recurring costs associated with acquisitions, including various transaction and certain integration costs.
(2)
This impairment charge results from the Company’s decision to exit the Medicare Advantage Prescription Drug product for 2027 as that product does not align with the Company’s strategic shift to focus exclusively on dual eligible members in Medicare.
(3)
The nine months ended September 30, 2026 primarily includes non-recurring termination benefits, and the nine months ended September 30, 2025 includes non-recurring litigation costs.
-MORE-
Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results
Page 10
October 21, 2026
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)
2026 GUIDANCE
Amount
Per Diluted Share
(2)
GAAP Net income
$
122
$
2.38
Adjustments:
Acquisition-related expenses
48
0.89
Amortization of intangible assets
36
0.70
Impairment
93
1.82
Other
21
0.44
Subtotal, adjustments
198
3.85
Income tax effect
(1)
(50)
(0.98)
Adjustments, net of tax
148
2.87
Adjusted net income
$
270
$
5.25
__________________
(1)
Income tax effect calculated at the statutory tax rate of approximately 25.5%.
(2)
Computations assume approximately 51.4 million diluted weighted average shares outstanding.
-END-